Biocurious: With psychedelic therapies gaining cred, Tryptamine offers patients and investors the trip of a lifetime
Tryptamine is focused on using psilocybin to treat difficult mental health and neurological conditions
In league with Swinburne University, the company will launch a groundbreaking binge eating disorder trial using intravenous delivery
With government and regulatory attitudes rapidly evolving, the company says the first FDA-approved psychedelic treatment is nigh
The CEO of local psychedelic drug developer Tryptamine Therapeutics (ASX:TYP), CEO Jason Carroll isn't afraid to make the big call.
His bold prediction?
The US Food & Drug Administration (FDA) will approve a mind-altering agent for a broad mental health indication by the end of next year, after decades of psychedelics being in the drug-development wilderness.
Carroll says several drug developers are close to amassing enough clinical data to front the agency.
The Nasdaq-listed Compass Pathways is in phase III trial stage for using psilocybin – a.k.a. 'magic mushrooms' – for treatment-resistant depression (TRD).
A read-out is due later this year.
'Compass will have the data buttoned down and I think they will present a good proposal to the FDA,' he says.
'They will produce the data the world wants to see on psilocybin and its efficacy.'
Most drug developers don't exactly wish their rivals the best of success, but Carroll says what's good for Compass benefits the whole nascent sector.
'It will help the market to understand there is a viable pathway to approval.'
Turn on, tune in and don't drop out
In the early 1970s Richard Nixon's war on drugs halted medical research on psychedelics, which had amassed plenty of – er – real-world evidence in the 1960s.
Trippy hippies aside, hundreds of formal LSD trials had been carried out since the 1940s.
As the protest-era Bob Dylan crooned, the times they are a-changin'.
In 2019 the FDA granted psilocybin 'breakthrough' status, enabling potentially fast-track registration.
In a February 2023 surprise, the Australian Therapeutic Goods Administration said it would allow authorised psychiatrists to prescribe psilocybin and MDMA (a.k.a. molly or ecstasy).
This was to treat TRD and post-traumatic stress disorder (PTSD) respectively.
Now, new US health secretary Robert F Kennedy Junior keenly supports advancing psychedelic therapies.
Carroll says while the laws are changing, 'the challenge is to bring pharmaceutical rigour to the category'.
In effect, the sector needs to transcend the reputation of the microdosing worried well at $1000 a night at Californian wellness retreats, as portrayed by Nicole Kidman's character in Nine Perfect Strangers.
'The world needs to see efficacy data, not just trendy buzzwords,' he says.
Make room for the 'shroom
Tryptamine's drug of choice – so to speak – is a synthetic version of psilocybin, the active ingredient in magic mushrooms.
Psilocybin currently is being researched in no fewer than 25 indications.
Tryptamine is targeting three overlooked disorders: binge eating disorder (BED), fibromyalgia and irritable bowel syndrome (IBS).
IBS affects about 6-8% of the population, BED 2-3% and fibromyalgia 3-5%.
'These are significant conditions, and they are less discussed from a neurological viewpoint,' Carroll says.
Tryptamine has completed phase II studies for BED and fibromyalgia, while an IBS study is ongoing.
These trials have used an oral version of the drug, TRP-8802.
In a world first, the company is poised to carry out a BED trial using an intravenous (IV) infused version, TRP-8803.
TRP-8803 uses the psilocybin metabolite psilocin.
IV takes the direct route
Carroll says IV delivery is better controlled, with a faster effect because the agent goes directly from bloodstream to brain.
While oral delivery is more convenient, IV infusions ensure the products are taken in the right dosage under the right supervision.
'The results are known quickly, whereas with oral delivery it takes one or three hours for an effect,' he says.
IV delivery offers practical and commercial benefits, because an oral patient might have to be in the supervised clinic for up to 10 hours.
'If you can treat four or five patients in a day instead of one, it makes a significant difference.'
IV delivery also avoids the big variabilities in the level of patient-by-patient responses, which are hit or miss.
The BED trial follows an IV safety study in Adelaide last year, enrolling 14 healthy volunteers.
Let's put binge eating to BED
BED is the most common eating disorder in the US and second most prevalent in Australia.
Patients may suffer depression, anxiety, PTSD and compulsive behaviours.
Carried out at the University of Florida, the phase 2a TRP-8802 trial showed a mean reduction of more than 80% in binge eating, as well as a 60% reduction in anxiety and 45% decline in depression.
This was after a single dose, over three to four months.
Tryptamine last month inked a clinical trial research deal with Swinburne University, by which the house of learning carries out the world's first BED trial using the IV-based TRP-8803.
Starting in the June quarter, the study entails two six-person cohorts being dosed two weeks apart (accompanied by psychotherapy).
Each cohort will receive two doses, either high or mid-range.
The trial assesses the safety, feasibility and efficacy of TRP-8803.
The company expects top-line results from the open-label study in the December quarter.
Fibromyalgia and IBS
Suffered by about one million Australians and 10 million Americans, fibromyalgia stems from the brain and manifests itself as pain throughout the body.
Doctors often dismiss the condition as 'all in the head' and they are right – but not in the dismissive manner intended.
The company's five-patient study was done at the University of Michigan, which specialises in chronic pain.
Reported in August last year, the results showed not only reduced pain, but improved sleep and cognitive functions.
Meanwhile the trial of the 'neuro-gastric' condition IBS was done at the esteemed Massachusetts General Hospital.
Interim results last December showed a 75% pain reduction in the first four of up to 10 patients, as well as a 'meaningful decrease' in anxiety.
Tryptamine expects final results by mid 2025.
Cashed up and ready to dose
Courtesy of a $6 million placement last year, Tryptamine held cash of $4.58 million as of the end of March, with a further R&D tax refund of $900,000 to $1 million to come.
Carroll says this will fully fund the study.
The placement was backed by luminaries including Dr Daniel Tillett, a medical entrepreneur and the force behind cancer drug developer Race Oncology.
Tillett has become a Tryptamine non-executive director.
Carroll says Tryptamine is happy to stick with psilocybin, rather than dabble in MDMA, LSD or the ultra-trendy horse tranquilliser ketamine.
'Psilocybin is the gold-standard psychedelic,' he says.
'It's the safest because it's non-addictive with a high dosage needed to make you ill.'
Ultimately, psychedelics are not so much about blocking the pain, but re-wiring how the brain works.
'People with depression have a certain way of thinking about themselves and if you break that cycle, they will be much more comfortable with their condition.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
2 hours ago
- ABC News
WA woman unable to legally undergo IVF in home state became 'reproductive refugee'
As a professional woman in her 30s who was not yet sure if she wanted to have children, Jane* decided to freeze her eggs to give her future self the choice. Four years later, she decided the time was right. But when Jane went back to the fertility clinic, she was told she could not use her frozen eggs for in-vitro fertilisation (IVF), the most common type of assisted reproductive technology. Why? Because she was a single woman who did not have reproductive health problems. And because she lived in Western Australia. While every state and territory in Australia has its own laws concerning IVF, WA is the only one that still rules out an unpartnered woman from accessing the procedure unless a doctor deems her to have reproductive problems (along with other restrictions against same-sex couples). "To my shock and surprise … I was not eligible to access my own eggs and use them for the final stages of IVF and that's because I was not classified as 'sub-fertile'," Jane told the ABC's Life Matters program. "I think part of the hurt, disappointment and frustration is that it's the 21st century. "In other parts of Australia women who are not partnered are able to access IVF, and yet in WA, because I chose to do it unpartnered, I was pretty much being discriminated against." WA laws allow IVF for women who can't conceive due to medical reasons, but explicitly excludes age as a valid reason. "The only option within WA that was offered to me was to undergo several rounds of intra-uterine insemination … which would still cost thousands of dollars per round and has a relatively low success rate," Jane said. Intra-uterine insemination is when sperm are inserted directly into the uterus, so in that scenario Jane — who was now in her late 30's — would not be using her frozen eggs which were four years younger — equating to healthier and likely more fertile. She was told the success rate of that procedure at her age at the time was 10 to 15 per cent per round, compared to an estimated success rate with IVF of 40 per cent. Jane searched for other options and found one — sending her eggs, and herself, to another state to undergo IVF. "That in itself was a challenge because the clinic in WA indicated they would only transfer my eggs to another fertility clinic interstate that was part of the same chain of clinics, so I was limited in my choice,' she said. She was lucky and found a clinic, and a fertility specialist, willing to assist her on the east coast. But the experience of travelling to an unfamiliar place without her support network to undergo the procedure made her feel like a "reproductive refugee". "When you're going through something as life-changing as IVF, it makes a challenging situation even more difficult," she said. It was also expensive. "I would estimate the costs of the egg freezing plus having to go interstate to undergo IVF would be in excess of $20,000," Jane said. "And there was no guarantee it would work." Jane said what made the whole process "rather harrowing" was that the clinic in WA told her to keep the transfer of her eggs interstate, and the procedure, "very quiet". Stephen Page, one of the nation's leading fertility lawyers and secretary of the Fertility Society of Australia, said nothing Jane or the clinic did was illegal. "Number one, Jane is the owner. Number two, under the constitution you have freedom of interstate trade, commerce and intercourse," he said. "And number three, in Western Australia there are restrictions about moving donor eggs, donor sperm and donor embryos, you need permission of the Reproductive Technology Council — but these eggs, her eggs, were not donor eggs, so she had full freedom to move them," he said. "But the Western Australian legislation is quite clear, that if you act outside your licensing conditions then the clinic can lose its WA licence [and] the clinician can commit an offence." Mr Page, along with many other experts and individuals, has long been calling for the legislation in WA to be updated — and while the state government said it had done much work on this, no changes have yet been made. In January 2018, the then newly-elected Labor government announced an independent review of WA's assisted reproductive technology (ART) and surrogacy legislation. The report, by associate professor Sonia Allan, found the laws discriminatory on the grounds of sex and relationship status, leading to the government to introduce the Human Reproductive Technology and Surrogacy Legislation Amendment Bill 2018. WA Premier Roger Cook was health minister in 2019 when the bill failed to pass the upper house after Liberal MP Nick Goiran gave one of the longest filibuster speeches in the state parliament's history, succeeding in delaying a vote on the laws. The bill then languished in parliament as attention turned to voluntary euthanasia before the COVID pandemic came along and up-ended most plans. In 2021, WA Labor won a historic victory, giving the party total control of both houses — yet even in those four years nothing was done. And despite Labor's strong result in the March 2025 election, the upper house now includes five crossbench MPs who could wield some influence, and Mr Goiran is also still in the chamber. But the government insists the legislation is important. "Reviews have highlighted that the current laws have prevented people from fulfilling their desires to create a family and also resulted in Western Australians having to travel interstate and overseas to access ART services," a government spokesperson responded to questions from the ABC. They insist new legislation is in development. "The bill will support more WA families and individuals to be able to access IVF and surrogacy to start or expand their families in line with other Australian jurisdictions." Jane's journey with IVF has been successful. She is now 30 weeks pregnant and due to have a girl. "It's really important to me that she grows up and she has bodily autonomy and reproductive freedom," Jane said, overcome by emotion when talking about her daughter's future. "Access to assisted reproduction should be open to solo parents by choice, gay singles and couples, widows, women who have survived domestic violence and still want to have kids but outside a partnership. "I urge the WA government to really make updating these laws a priority. *We have changed Jane's name to protect her identity, at her request.
ABC News
3 hours ago
- ABC News
SA researchers expand baby heel-prick screening to help find rare conditions
When Max was three days old, he was diagnosed with a rare and life-changing condition called phenylketonuria, commonly known as PKU, through a newborn blood screening test. The condition is one of more than 30 which can currently be detected in newborns through heel-prick blood samples to help identify and treat serious health conditions early. Now, researchers in South Australia are working to expand the screening program to detect more than 600 genetic conditions. PKU is an inherited blood disorder which can affect how the body processes protein and can eventually lead to serious health problems if left untreated. "[It's] actually the condition that started the whole newborn screening program in the 1960s," explained South Australian researcher Professor Karin Kassahn. "It's one of the metabolic conditions where the body can't process protein, phenylalanine in particular [which is] a certain amino acid, in the way it usually would … so by picking this up at birth, then the diet can be modified." The heel-prick test method was developed by American microbiologist, Dr Robert Guthrie, whose niece was diagnosed with PKU at 13 months — too late to prevent early brain damage. Since 1960, the program has been rolled out across much of the world as a routine test for newborns — and expanded to be able to accurately and quickly detect more than 30 conditions. Twins, Max and Blake, underwent the screening as newborns. Their parents, Hannah and Robert Macbeth, had no idea PKU existed when Max was first diagnosed. "We'd never heard of it," Ms Macbeth said. "We kind of cried about it until it kind of realistically hit us and we went, 'You know what, we can manage this. We've caught it early'." Mr Macbeth said he was worried his son would have to follow a restricted diet for life. "We're quite a barbecuing family so we love our meats and that sort of thing and entertaining," he said. Thanks to early detection and intervention, Max's protein levels are closely monitored with weekly at-home prick tests, and he uses a medication to help lower his blood phenylalanine levels. "We're very lucky," Ms Macbeth said. "We could have been in all sorts of dramas for him because it can be pretty serious if left undiagnosed." Untreated, PKU can lead to irreversible brain damage and intellectual disability, neurological conditions such as seizures and tremors, and problems with behaviour, emotions, development and health. But for now, things are looking positive. "He'll live a relatively normal life, he might just be a bit different with food at school and stuff," Ms Macbeth said. "It's just managing it and it's quite easy at the moment … he's a happy little soul," Mr Macbeth added. The couple said they thought expanding the testing program would be "brilliant". "If we can do testing that picks up these things when they're little and there are things we can put in place to help reduce [the risk of] something happening in the long run or causing a bigger issue, then we would be mad not to do it," Ms Macbeth said. Professor Kassahn is the principal investigator on the NewbornsInSA study which is combining genomics and metabolomics in a bid to detect more treatable conditions, earlier. "Many of the conditions we screen for are rare, so individually people will probably not have heard of many of them — cystic fibrosis and PKU are probably the more familiar ones, but collectively they actually constitute quite a significant health burden," she said. "They are the primary cause of childhood admissions to hospital and also ongoing health problems. "Early detection allows early intervention and treatment, and just as the current program has really saved thousands of lives, we're hoping by expanding on that program … we can make a difference to the health outcomes for these babies." The researchers are looking for conditions including immune deficiencies, conditions of metabolic dysregulation, congenital deafness, and neurological conditions. Professor Kassahn said the study collaboration between SA Pathology, the Women's and Children's Hospital and the University of Adelaide was "well underway" with 250 families already enrolled, out of their target of 1,000. The team has already made some significant findings — with early intervention now in place for those families to help treat or manage their rare diagnoses. "We've issued five of what we call a 'high chance report' and those would have otherwise been undetected," she explained. "Those families are being managed through the clinical teams at the Women's and Children's Hospital." She said eligible families are still able to take part in the study with enrolment via the NewbornsInSA website.
SBS Australia
3 hours ago
- SBS Australia
Sarah thought a bike accident was the most painful thing. Then at 50, perimenopause hit
Turning 50 brought great challenges for Justine. Source: Supplied SBS turns 50 in 2025 and so do hundreds of thousands of Australians. Insight asks — is turning 50 a big deal? From mid-life crises to menopause, finding undiscovered family members and starting afresh, watch Insight episode Turning 50 Tuesday 10 June at 8.30PM on SBS or live on SBS On Demand . Perimenopause hit Justine Christerson hard six months before she turned 50. It followed a major accident where, during a competition, a BMX rider ran off track and straight into Justine — leaving her bed-bound for 16 weeks with a broken sacrum (the large triangular bone that stabilises the pelvis). With constant pain, hot flushes , mood swings and uncontrollable outbursts, Justine empathises with her husband. "You've got a partner wondering: 'who is this person'? What's going on?' Justine told Insight. "And if they are not understanding and supportive ... it could be a very explosive situation". "For me, turning 50 was feelings, emotions and questioning who I was, and where I am with my life — and dealing with my aggression [brought on by perimenopause] that was internally combusting," she said. Now 51, Justine is still using a walking stick because of her accident. She recognises some of her pain is related to her accident, but some is related to the stages of menopause. She wants more people to recognise that you're not going crazy when perimenopause symptoms kick in around her age. Like Justine, turning 50 brought challenges for Sarah Hennesey. She believed that by the time she turned 50, she would be living on a big country property with her lawyer husband and seven children — running the local Country Women's Association and baking scones. None of those things happened. Sarah and her husband separated when she was 42; she says that life in the eight years since has been "upside down, inside out". "The house had to be sold [during the separation]," Sarah said. "We had been working for a long time but for various reasons there wasn't much to show for it." For years, she had been working in highly paid, high-stress jobs and says she had relied too heavily on alcohol. Getting sober in her late 40s brought great clarity for Sarah. So, when she lost her job at age 49, she chose to take a chance on her creative passion. "I thought: 'you know what, I'm almost 50. I don't care anymore'," Sarah said. "I have this deeper sense that things will be okay, and not to think that I can control everything. "I have learned the hard way so many times that I can't..." After enrolling in a business course, Sarah started her own business catering events and teaching people how to make mocktails and non-alcoholic drinks. "I made the decision to get my business up and running before my 50th because in this new significant chunk in my life, I knew that things needed to be different". Unlike Sarah, Matt Craig is not looking at modifying aspects of his life anytime soon. When asked whether he's having a mid-life crisis at all, Matt told Insight that "if buying cool shit, cool cars is a reflection of a midlife crisis, f---, I hope I have them regularly". A Gold Coast construction manager with a penchant for collecting cars and attending bush doofs (electronic dance festivals in remote locations), Matt hasn't slowed down since turning 50. "Fifty-year-old hangovers are certainly different from younger ones," Matt said. "But other than that ... just keep it strong. Keep it real and keep charging". Although leading a fast and colourful lifestyle that makes him feel closer to 35, there is one area of Matt's life where he admits to needing a little support ... the bedroom. "You like to make sure the old fella gives a good showing, but you've just got to get it right with the timing and make sure you set the mood — otherwise, you're left with a hard problem." Like Mike, Tania Segura loves being 50. A secondary teacher by day and dance instructor by night, Tania says her 40s were better than her 30s and her 30s were better than her 20s, so she can only imagine how great her 50s are going to be. "I'm finding that now there's space for joy," Tania said. "To wear a cute dress or use the good China ... I think life is for living and I'm here for it." Finding the space to try new things, Tania recently entered an Instagram competition and won a photoshoot. She is now signed to a talent and casting agency, which is something she could not have imagined doing when she was younger. "Sometimes, people expect 50, to be old and to be lacking vitality," Tania said. "I'm still working and I'm still dancing ... I'm not in an armchair, crocheting with a cup of tea. "I think we've had 50 years to put plants in this garden, and it's now time to bloom." Similarly to Tania, Sarah feels like now is the time to forge new paths, and says she now has "laser sharp focus". "No more mucking around — I'm not going to get another 50 years," Sarah said. "It's on the downhill slide and I don't see that as a bad thing; I see it as giving the gift of clarity." However, for Justine, this midlife point has not been quite the time she hoped for and is eager to be on the other side of it. When Insight asked her what she was looking forward to in the future, it was "not being 50" and "not having menopause". "I'm really looking forward to the day I turn around and say, 'what was all that about'?" Share this with family and friends
